Our results reveal that AXL–GAS6 signal axis potentially has a key role in NSCLC tumor progression and survival prognosis; and AXL alone or in combination with GAS6 may serve as feasible biomarker for prognostic prediction in patients with metastatic NSCLC to the brain. This evidence concerns the gene AXL and neoplasm.